Earlier this week, InVivo Therapeutics (NASDAQ: NVIV) announced that the sixth-implanted patient in the INSPIRE clinical study improved from complete AIS-A spinal cord injury to an incomplete AIS-B spinal cord injury. This is the fourth patient to show improvement from the INSPIRE trial, equating to two-thirds of the first six patients enrolled in the study….
Company Obtains Funding For Initiation Of Phase I/II Clinical Trial Last week, at the American Association for Cancer Research (AACR) annual meeting, scientists from BriaCell Therapeutics Corp. (TSXV: BCT) (OTC: BCTXF) presented research on the molecular profile of BriaVax™, the company’s proprietary whole tumor cell vaccine. The findings (AACR #2369) are suggestive of the BriaVax™ mechanism…
A team of researchers from Gothenburg University in Sweden presented data from a Phase 4 study on Ceplene® earlier this week at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA. These data could have a profound impact on future use of the drug in elderly patients with Acute Myeloid Leukemia (AML)….
In the past week, BriaCell Therapeutics Corp (BCT.V) (BCTXF) provided an update for investors on the status of BriaVax™, the company’s proprietary whole tumor cell vaccine for the treatment of late-stage cancer. I continue to be intrigued by BriaCell and what the company is doing in immuno-oncology. The stock is largely unheard-of by retail investors…
Last month I wrote a detailed article introducing investors to Oasmia Pharmaceuticals (NASDAQ:OASM), a Swedish-based biopharmaceutical company developing next-generation novel formulations of well-established chemotherapeutic agents through its proprietary nanotechnology platform. Shares of Oasmia are up 50% since that article, and I think the upward momentum in the stock will continue based on some recent positive…
BioSig Technologies, Inc. (BSGM) is a Minnesota-based medical device company developing a proprietary technology platform designed to improve the rapidly growing multi-billion dollar electrophysiology (EP) marketplace. The company’s leading product is Pure EP™, a surface electrocardiogram (EKG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists during catheter ablation procedures to treat cardiac…
Over the past several months, Immune Pharmaceuticals (IMNP) has aggressively expanded its efforts in oncology. The company has a two-fold strategy with its oncology pipeline, develop a platform of next-generation nanoparticle cytotoxic agents and bispecific antibodies, and resurrect legacy drug candidates acquired via the company’s acquisition of EpiCept in late 2013. If successful, Immune’s desire…
The Society for Research on Nicotine & Tobacco (SRNT) held its Annual Meeting in Chicago, IL on March 2-5, 2016. At that meeting, 15 independently conducted scientific studies with SPECTRUM® Cigarettes were presented in oral presentation or poster form. SPECTRUM® is a brand of “research cigarette” commissioned by the National Institute on Drug Abuse (NIDA), along with…
Oasmia Pharmaceuticals AB (NASDAQ: OASM) is a Swedish-based biopharmaceutical company developing next-generation novel formulations of well-established chemotherapeutic agents through its proprietary nanotechnology platform. Compared to existing cytostatic agents, Oasmia’s improved formulations offer reduced side-effects, potentially leading to expanded therapeutic use, as well as reduced infusion time, better pharmacologic profile, and superior bioavailability. The lead product…
On February 25, 2016, RedHill Biopharma Ltd. (RDHL) reported financial results for the fourth quarter and full year ending December 31, 2015. The company also hosted a conference call with investors to highlight the operational results from 2015 and provide an update on the late-stage pipeline. There are a tremendous number of catalysts for RedHill…